Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
Open Access
- 1 July 2011
- journal article
- research article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 30 (7), 1375-1381
- https://doi.org/10.1377/hlthaff.2011.0231
Abstract
The US Food and Drug Administration is often criticized as inefficient compared to its European counterpart, the European Medicines Agency. This criticism is especially common in the field of oncology, where severely ill patients have few therapeutic options. We conducted a direct drug-to-drug comparison of the two regulatory agencies’ approvals of new oncology drugs. We found that contrary to public assertions, the median time for approval for new cancer medicines in the United States was just six months—and that these new anticancer medicines are typically available in the United States before they are in Europe. Our findings reinforce the need for strong financial and public support of the Food and Drug Administration, so that such medicines can continue to be made available speedily to patients in need.Keywords
This publication has 20 references indexed in Scilit:
- MifamurtidePediatric Drugs, 2010
- Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancerCancer Management and Research, 2009
- Degarelix for the treatment of prostate cancerDrugs of Today, 2009
- Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of ImatinibClinical Cancer Research, 2008
- Treanda approved for chronic lymphocytic leukemiaAmerican Journal of Health-System Pharmacy, 2008
- Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell LymphomaClinical Cancer Research, 2007
- Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialBlood, 2006
- Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes FailsJournal of Clinical Oncology, 2005
- STI571 (imatinib mesylate): the tale of a targeted therapyAnti-Cancer Drugs, 2002
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999